(Q79345406)
Statements
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (English)
Jagannath S
Richardson PG
Sonneveld P
Schuster MW
Irwin D
Facon T
Harousseau JL
Cowan JM
Anderson KC
9 November 2006